Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture
NCT01878383 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12550
Last updated 2020-09-09
Summary
PCR detection of HSV DNA shedding in the female genital tract using the GeneXpert system (Cepheid, Sunnyvale CA) will be compared with traditional (routine) PCR (pregnant and nonpregnant women) and with HSV culture (nonpregnant women). The GeneXpert system performs all sample-processing steps and real-time PCR in a single integrated cartridge. The standard cartridge is an inexpensive disposable plastic cartridge with filtration and ultrasonic lysis capabilities. It consists chiefly of several combined molded plastic components: a cartridge body containing eleven fluid reservoirs or chambers along with an attached PCR tube, a specialized valve body with an ultrasonic interface containing a sub-micron filter and glass lysis beads, and a rotary valve with an axial syringe barrel. The operation of the cartridge is simple. The rotary valve contains an inlet and an outlet port. Fluid such as a sample buffer can be drawn up into a syringe drive through the inlet port of the rotary valve and then dispensed into any other chamber within the cartridge by rotating the valve and expelling the fluid through the outlet port. The fluid can either be passed through a filter contained within the valve assembly or it can be passed directly into the next chamber without filtration, depending on the path that is chosen. The cartridge fluidics and subsequent real-time PCR all are performed within the GeneXpert instrument. The GeneXpert contains multiple modules (ICORE units) that can be independently programmed to drive the syringe/rotary valve, and to perform four-color real-time PCR. Each cartridge fits inside one module, and all processing, PCR, and analysis steps are performed automatically. Each ICORE module can be run and analyzed independently, so batching of samples is unnecessary.
Conditions
- Herpes Simplex Virus
Interventions
- DEVICE
-
Genexpert assay
Sponsors & Collaborators
-
University of Alabama at Birmingham
lead OTHER
Principal Investigators
-
David W Kimberlin, MD · University of Alabama at Birmingham
-
Richard Whitley, MD · University of Alabama at Birmingham
Eligibility
- Min Age
- 19 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-01-31
- Primary Completion
- 2019-12-31
- Completion
- 2019-12-31
Countries
- United States
Study Locations
More Related Trials
-
Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2
NCT01112956 ·Status: COMPLETED
-
An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.
NCT04950712 ·Status: COMPLETED
-
A Two Arm, Multi-Site Clinical Evaluation of the ARIES HSV 1&2 Assay in Symptomatic Patients
NCT02092233 ·Status: COMPLETED
-
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
NCT03146403 ·Status: TERMINATED ·Phase: PHASE2
-
Comparative Effectiveness of Treatment Options for Genital Herpes Infection to Reduce Adverse Pregnancy Outcomes
NCT02986802 ·Status: COMPLETED
-
Herpevac Neonatal Substudy
NCT00138320 ·Status: TERMINATED
-
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
NCT06033261 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
NCT00076232 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes
NCT06385327 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Evaluation of the Sentosa SA HSV1/2 Qualitative PCR Test
NCT02685956 ·Status: COMPLETED
-
HerpeSelect® Express Rapid Test Study Protocol: Sexually Active Adult Population
NCT00655434 ·Status: COMPLETED
-
Trial Evaluating Safety, Tolerability and Immune Response of AG-707
NCT00231049 ·Status: COMPLETED ·Phase: PHASE1
-
Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis
NCT02265913 ·Status: COMPLETED ·Phase: PHASE3
-
Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
NCT00362297 ·Status: COMPLETED ·Phase: PHASE4
-
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
NCT00740584 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over
NCT06569823 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Evaluating New Formulation of Therapeutic HSV-2 Vaccine
NCT02515175 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant
NCT00697567 ·Status: COMPLETED ·Phase: PHASE2
-
Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes
NCT01687595 ·Status: COMPLETED ·Phase: PHASE2
-
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
NCT02114060 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons
NCT00079911 ·Status: TERMINATED ·Phase: PHASE4
-
Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines
NCT00698490 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation
NCT00723229 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2
NCT04222985 ·Status: TERMINATED ·Phase: PHASE1
-
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
NCT02837575 ·Status: COMPLETED ·Phase: PHASE2